Leiomyosarcoma Clinical Trial
Official title:
A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
The goal of this clinical research study is learn if taking Femara (letrozole) after a hysterectomy (surgical removal of the uterus) for uterine leiomyosarcoma will delay or prevent the cancer from coming back.
Letrozole is an aromatase inhibitor. Aromatase is the enzyme that produces estrogen in
post-menopausal women. By interfering with the production of estrogen triggered by aromatase,
letrozole reduces the total amount of estrogen in the body. As a result, less estrogen can
reach cancer cells, thus preventing their growth.
Before you can start treatment on this study, you will have "screening tests." These tests
will help the doctor decide if you are eligible to take part in this study. These exams,
tests, or procedures are part of regular cancer care and may be done even if you do not join
the study. If you have had some of them recently, they may not need to be repeated. This will
be up to your study doctor.
Your complete medical history will be recorded, and you will have a physical exam (including
a pelvic exam). Your vital signs and blood pressure will be measured. Blood (about 2-3
teaspoons) will be drawn for routine tests. You will also have a blood test (1 teaspoon) to
check your cholesterol. You will have an electrocardiogram (ECG -- a test that measures the
electrical activity of the heart). You will also have a chest x-ray, and either a computed
tomography (CT) scan or a magnetic resonance imaging (MRI) to check the status of the
disease. Your doctors will test previously collected tumor tissue to learn if the estrogen
receptor is positive or negative.
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in the toss of a coin) to 1 of 2 groups. Group 1 will receive letrozole by mouth once a day.
Group 2 will receive no treatment. Both groups will be followed closely every 3 months. You
will have an equal chance of being placed in either group.
If you are in Group 1, you will take letrozole by mouth every day for 12 weeks. Every 12
weeks is considered a study "cycle." You will only be given the amount of drug needed for 1
cycle of therapy at a time. You will keep a diary during the study that will list when and
how much drug you took. This diary will be reviewed after each cycle of therapy by the
research nurse or doctor and filed in your chart.
Every 12 weeks, all participants will have blood (about 3-4 teaspoons) drawn for routine
tests. CT scan of the chest, abdomen (stomach area), and pelvis will be done every 24 weeks.
In addition, all participants will have a physical exam (including a pelvic exam), and your
vital signs and blood pressure will be measured.
You may remain on study for as long as you are benefitting. You will be taken off study if
intolerable side effects occur.
Once you are off study, blood (about 2-3 teaspoons) will be drawn for routine tests and to
measure your cholesterol level. You will have a physical exam (including a pelvic exam), and
an MRI or CT scan.
This is an investigational study. Letrozole is approved by the FDA for treatment of some
breast cancer patients after surgery. Its use in patients with leiomyosarcoma is
experimental. Up to 80 patients will take part in this study. All will be enrolled at M. D.
Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
| Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
| Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
| Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
| Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
| Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
| Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
| Completed |
NCT00400569 -
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 |